Kuros Biosurgery was granted U.S. Patent No. 10,589,001, "Pharmaceutical formulation for use in spinal fusion," addressing the use of parathyroid hormone containing matrices for spinal fusion.
The company's Dutch subsidiary, Kuros Biosciences, was granted U.S. Patent 10,561,683, “Method for producing an osteoinductive calcium phosphate and products thus obtained," covering certain osteoinductive materials produced by Kuros’s proprietary production processes. This further expands the patent portfolio relating to Kuros’s MagnetOs product line.
These follow the granting in 2H19 of other patents related to the MagnetOs product family, specifically, Japanese Patent No. 6,559,665 and Australian Patent 2,016,229,595.
Joost de Bruijn, Chief Executive Officer of Kuros, said, “The granting of these patents both strengthens our position as a leader in this field and our ability to exploit that leadership for the benefit of our shareholders, our customers and their patients.”